Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.
Saved in:
| Title: | Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses. |
|---|---|
| Authors: | Foster L; Division of Hematology Oncology, University of Virginia, Charlottesville, VA, USA. LF5V@uvahealth.org., Anderson LD Jr; Myeloma, Waldenstrom's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Chung A; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Chaulagain CP; Department of Hematology and Oncology, Myeloma and Amyloidosis Program, Cleveland Clinic Florida, Weston, FL, USA., Pettijohn E; Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA., Cowan AJ; Division of Medical Oncology, Fred Hutch Cancer Center/University of Washington, Seattle, WA, USA., Costello C; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA., Larson S; Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Sborov DW; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Silbermann R; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Voorhees P; Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, USA., Krevvata M; Johnson & Johnson, Spring House, PA, USA., Pei H; Johnson & Johnson, Titusville, NJ, USA., Patel S; Johnson & Johnson, Horsham, PA, USA., Khare V; Johnson & Johnson, Horsham, PA, USA., Cortoos A; Johnson & Johnson, Horsham, PA, USA., Carson R; Johnson & Johnson, Spring House, PA, USA., Lin TS; Johnson & Johnson, Horsham, PA, USA., Badros A; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA. |
| Source: | Blood cancer journal [Blood Cancer J] 2025 Oct 06; Vol. 15 (1), pp. 154. Date of Electronic Publication: 2025 Oct 06. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-025-01355-0 |
